Pharmacology
Meduri 1998: Meduri protocol for unresolving ARDS (JAMA) (1998)
SCCOPE: Steroids for COPD exacerbations (NEJM) (1999)
​
MAPPET-3: Alteplase with or without heparin for sub massive PE (NEJM) (2002)
​
LaSRS: Late rescue steroids for ARDS (NEJM) (2006)
​
Meduri 2007: Meduri protocol for early ARDS (CHEST) (2007)
Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome (NEJM) (2010)
MOPETT: Alteplase for moderate PE (Am J Cardiol) (2013)
​
​
Sodium bicarbonate therapy for patients with severe metabolic acidemia in the intensive care unit (BICAR-ICU): a multicenter, open-label, randomized controlled, phase 3 trial (Lancet) (2018)
ROSE: Cisatracurium for early ARDS (NEJM) (2019)
​
Inhaled Pulmonary Vasodilators and Thoracic Organ Transplantation: Does Evidence Support Its Use and Cost Benefit? (Semin Cardiothorac Vasc Anesth) (2019)
​
DEXA-ARDS: Dexamethasone for early ARDS (Lancet) (2020)
​
ACTT-1: Remdesivir for COVID-19 (NEJM) (2020)
​
Editorial overview: Respiratory: Pulmonary pharmacology–The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives (Cur Opin Pharmacol) (2021)
​
Inhaled pulmonary vasodilators: a narrative review (Ann Transl Med) (2021)
​
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomized, controlled, open-label, platform trial (Lancet) (2023)
​
​
Hydrocortisone in Severe Community-Acquired Pneumonia (NEJM) (2023)
​
Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia (NEJM) (2023)
​
CAPE COD: Hydrocortisone for severe CAP (NEJM) (2023)
​
Mucolytic Medications (StatPearls)
​
​
​
​